First elected: 4th July 2024
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
Introduce 16 as the minimum age for children to have social media
Sign this petition Gov Responded - 17 Dec 2024 Debated on - 24 Feb 2025 View Alison Bennett's petition debate contributionsWe believe social media companies should be banned from letting children under 16 create social media accounts.
These initiatives were driven by Alison Bennett, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Alison Bennett has not been granted any Urgent Questions
Alison Bennett has not introduced any legislation before Parliament
Alison Bennett has not co-sponsored any Bills in the current parliamentary sitting
I have not discussed this with the Leader of the House. As announced in the policy paper ‘The fire safety of domestic upholstered furniture’, published on January 22, the Government will bring forward amendments to the Furniture and Furnishings (Fire) (Safety) Regulations 1988, in advance of longer-term reforms.
The SI will be laid when parliamentary time allows.
This Government is working to ensure we have a high-quality and professional construction industry, with consumer protection at the heart of this. TrustMark, sponsored by the Department and licenced by the Government, is the Government Endorsed Quality Scheme that covers work a consumer chooses to have carried out in or around their home. In addition, the Building Safety Act 2022 has introduced competence requirements for both individuals and businesses working in the built environment.
Any action that the Government takes on licensing to protect customers and standards needs to be robust, proportionate and evidence based.
Companies House does not have any plans to build a specific database for the purpose outlined.
Companies House is taking action to improve the quality of the information on the Register of Companies using powers made available by the Economic Crime and Corporate Transparency Act 2023.
The Act also provides for the compulsory identity verification of directors, persons with significant control and those acting on behalf of companies. This will ensure that consumers are able to more easily trace the previous appointments of company directors. The systems needed to enable the deployment of identity verification are currently being implemented.
There is a robust regulatory framework that addresses the health and safety risks associated with grid-scale battery storage. Specifically, the Health and Safety at Work Act and secondary legislation places legal duties on employers to manage risks to employees and anyone else who may be affected. It is the policy of the Health and Safety Executive to continue to review its regulatory framework to make sure it works in a time of innovation.
The department is committed to supporting the UK net zero carbon targets. Since 2021, our own building standards require that all new school buildings we deliver are net zero carbon in operation and are adapted to climate change.
The department is providing support for all schools and colleges to start on their journey towards net zero via our new online sustainability support for education platform and our climate ambassador programme. Where schools are considering options to become more sustainable, including considering decarbonisation of their energy supply, our ‘Get help for buying’ service provides support to ensure that schemes procured are of high quality and value to the sector. More information can be found at: https://gethelpbuyingforschools.campaign.gov.uk/.
Additionally, the department recently announced the £80 million Great British Energy Solar Accelerator Programme in partnership with GB Energy that will install solar and other technologies such as electric vehicle chargers in 200 targeted schools and colleges, prioritising those in areas of deprivation, to start in the 2025/26 financial year.
Details of other government funding available to public bodies for sustainability, prepared by the Crown Commercial Service can be found at: https://www.crowncommercial.gov.uk/social-value/carbon-net-zero/funding-and-grants.
Capital funding allocated to the school sector each year can also be used for projects that improve the energy efficiency and sustainability of school buildings, as well as improving the condition of the estate to keep schools safe and operational.
The department has allocated £2.1 billion in condition funding for the 2025/26 financial year, which is £300 million more than the previous year.
The adoption and special guardianship support fund (ASGSF) supports children previously in care who are under special guardianship orders, residency orders or child arrangements orders. We are not proposing wider eligibility changes at this point.
The ASGSF does not allow unused funds to be carried over from one financial year to the next. However, where applications were agreed and therapy started prior to April 2025, that therapy may continue under previously agreed transitional funding arrangements.
The adoption and special guardianship support fund (ASGSF) supports children previously in care who are under special guardianship orders, residency orders or child arrangements orders. We are not proposing wider eligibility changes at this point.
The ASGSF does not allow unused funds to be carried over from one financial year to the next. However, where applications were agreed and therapy started prior to April 2025, that therapy may continue under previously agreed transitional funding arrangements.
The government is not responsible for setting or making recommendations about teacher pay in further education (FE) colleges, including sixth form colleges which unlike 16-19 academies are part of the statutory FE sector.
The Autumn Budget 2024 set out the government’s commitment to skills, by providing an additional £300 million revenue funding for FE to ensure young people are developing the skills this country needs. The department recognises the vital role that FE teachers and providers play in equipping learners with the opportunities and skills they need to succeed in their education. The department will set out in due course how this funding will be distributed.
This builds on our investment to extend targeted retention incentive payments of up to £6,000 after tax to eligible early career FE teachers in key subject areas, including in sixth form colleges. The department is also delivering funding to support those young people who do not pass mathematics and English GCSE at 16, who are predominantly studying in FE.
The department has continued to offer financial incentives for those undertaking teacher training for the FE sector in priority subject areas. For the 2024/2025 academic year, training bursaries are worth up to £30,000 each, tax free, with further information about schemes for future years in due course. Additionally, we are supporting industry professionals to enter the teaching workforce through our Taking Teaching Further programme.
The Government shares the public’s high regard for the UK’s environmental protections, food standards and animal welfare. This Government will uphold and protect our high environmental and animal welfare standards in future trade deals. We will promote robust standards nationally and internationally and will always consider whether overseas produce has an unfair advantage
All agri-food products must comply with our import requirements in order to be placed on the UK market. This includes ensuring imported meat products have been slaughtered to animal welfare standards equivalent to our domestic standards
The Government recognises farmers’ concerns about imports produced using methods not permitted in the UK. We have been clear that we will use our Trade Strategy to support economic growth and promote the highest standards of food production.
We are seeking powers in the Home Office’s Crime and Policing Bill to provide statutory enforcement guidance to help councils make full and proper use of their fly-tipping enforcement powers. These include fixed penalty notices of up to £1000, vehicle seizure and prosecution action which can lead to a significant fine or even imprisonment.
We have committed to forcing fly-tippers and vandals to clean up the mess they have created as part of a crackdown on anti-social behaviour. We will provide further details on this commitment in due course.
Defra officials chair the National Fly-Tipping Prevention Group through which we work with a wide range of stakeholders, including officials from the Department for Transport, Ministry of Housing, Communities and Local Government and devolved governments, to promote good practice on preventing fly-tipping. Various practical tools are available from their webpage which can be found at: https://www.keepbritaintidy.org/national-fly-tipping-prevention-group.
GB operates a pesticides regime based on assimilated EU law and continues to base decisions on the use of pesticides on careful scientific assessment. This includes maximum residue levels, which are set below, and usually well below, the level considered to be safe for people to eat.
Defra keeps the GB pesticides regulatory framework under continued review so that the regime is efficient and effective in ensuring pesticides will not harm human health or pose unacceptable risks to the environment.
The Minister for Local Transport’s considerations on the Lower Thames Crossing scheme are explained in the Decision Letter, published on the Planning Inspectorate website, and this sets out the proposed mitigations regarding habitats, including woodlands. The Honourable Member will understand that during the 6-week legal challenge period the Department is unable to comment in detail, but National Highways will be able to answer further questions about the scheme.
The Government takes road safety seriously, and we are committed to reducing the numbers of those killed and injured on our roads. My Department has begun work on a new Road Safety Strategy, the first in over a decade, and will share more details in due course.
The Government is listening closely to the concerns of those affected by tragic cases of death or serious injury on our roads.
The Department does not hold the data requested.
The receipt of War Pensions and Armed Forces Compensation Scheme (AFCS) awards is already fully ignored when calculating eligibility for Universal Credit.
This is in line with the treatment of civil compensation payments for personal injury, which are usually in the form of lump sum payments and are disregarded as capital.
Periodic payments of civil compensation (i.e. income) in consequence of a personal injury either ordered by the court or under an agreement are fully disregarded.
The first £10 per week of a War Pension or AFCS award is disregarded in: income-related Employment and Support allowance; income-based Jobseeker’s Allowance; and Income Support. Armed Forces Independence Payments are fully disregarded in these benefits and can also allow the recipient to qualify for an additional disability amount. This contrasts with a benefit like Industrial Injuries Disablement benefit where there is no weekly disregard. Furthermore, these are legacy benefits, in the process of being replaced by Universal Credit, in which War Pensions and AFCS are ignored.
By default, the first £10 per week of a War Pension or Armed Forces Compensation Scheme is disregarded in Housing Benefit. Furthermore, a discretionary scheme allows local authorities to fully disregard them.
In relation to Pension Credit, the first £10 of any War Pension payments or AFCS award made due to injury or disablement is disregarded. Four additions to the War Disablement Pension are completely disregarded: Constant Attendance Allowance; Mobility Supplement; Severe Disablement Occupational Allowance; and dependency increases for anyone other than the applicant or her/his partner.
War Pensions and AFCS awards are a qualifying income for the Savings Credit element of Pension Credit, which is available to those who reached State Pension age before April 2016. Armed Forces Independence Payments are fully disregarded in Pension Credit and can also allow the recipient to qualify for an additional disability amount.
The income taper in Housing Benefit ensures people in work are better off than someone wholly reliant on benefits. The Department acknowledges, however, there is a challenge presented by the interaction between Universal Credit and Housing Benefit for those living in Supported Housing or Temporary Accommodation and receiving their housing support through Housing Benefit. The department will consider the issue carefully in partnership with stakeholders.
Notwithstanding these positive outcomes from work, the Department acknowledges there is a challenge presented by the interaction between Universal Credit and Housing Benefit for those residing in Supported Housing or Temporary Accommodation and receiving their housing support through Housing Benefit. The department will consider the issue carefully in partnership with stakeholders.
The Pension Protection Fund rules on indexation have been the subject of much discussion. I will continue to consider this issue, and the valuable report of the Work and Pensions Select Committee report from March 2024. The Government will respond fully to its recommendations in the coming months.
We want new mothers to be able to take time away from work in the later stages of their pregnancy and in the months following childbirth, in the interests of their own and their baby’s health and wellbeing. Maternity pay is paid for each pregnancy, not in respect of each child. For paternity pay, it is also paid at the statutory rate, even if you have more than one child, for example twins.
Parental pay is reviewed annually at the discretion of the Secretary of State for Work and Pensions. From April 2025, the rate will increase by September 2024's CPI figure of 1.7%, subject to parliamentary approval, from £184.03 to £187.18 per week.
Parental pay is only one element of the support available for parents. Depending on individual circumstances, additional financial support, for example, Universal Credit, Child Benefit and the Sure Start Maternity Grant (a lump sum payment of £500) may also be available.
The Sure Start Maternity Grant is a grant of £500 to provide help with the costs associated with the expenses of a baby (or babies in the event of a multiple birth) expected, born, adopted, or the subject of a parental or residence order or other similar arrangements if there are no other children under the age of 16 in the claimant’s family. You might be entitled to more than one payment in the event of a multiple birth.
The National Institute for Health and Care Excellence’s (NICE) guidance on Parkinson’s disease in adults sets out the best practice for healthcare professionals in the care, treatment, and support of people with Parkinson’s. It aims to improve the recognition and management of Parkinson’s symptoms. The NICE’s guidance on Parkinson’s disease in adults is available at the following link:
https://www.nice.org.uk/guidance/ng71
NHS RightCare has also produced a Progressive Neurology Conditions Toolkit. The toolkit sets out the key priorities for increasing knowledge of the signs and symptoms of Parkinson’s and makes suggestions regarding new service models which can be implemented in primary care to speed up referrals to specialists and ensure a timely diagnosis. Additionally, the Getting It Right First Time Programme for Neurology has published a National Speciality Report, which makes several recommendations in relation to reducing waiting for neurology services. NHS England has also established a Neurology Transformation Programme, a multi-year, clinically led programme which has developed a new model of integrated care for neurology services, to support integrated care boards to deliver the right service, at the right time for all neurology patients, including those with Parkinson’s.
Data on how regularly an average patient with Parkinson’s disease sees a neurologist is not held centrally. NICE guidance recommends that people with Parkinson's should be seen at regular intervals of six to 12 months. While NICE guidance is not mandatory, the Government expects the healthcare system and commissioners to take the guidelines fully into account when designing services for their local population, and to work towards their implementation over time.
Data on the average time taken for patients with Parkinson’s disease to see a neurologist is not held centrally. The latest data for referral to treatment waiting times in England, from February 2025, shows there were under 230,000 pathways waiting for a neurology appointment, 53.7% of which were waiting within 18 weeks.
The NHS Constitution sets out that patients should start consultant-led treatment within a maximum of 18 weeks from referral for non-urgent conditions. On 6 January 2025, NHS England published the new Elective Reform Plan, which sets out a whole system approach to hitting the 18-week referral to treatment target by the end of this Parliament. We have achieved our pledge to deliver two million extra elective appointments. These additional appointments have taken place across a number of specialities, including neurology. We have made the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the NHS constitutional standard, by March 2029.
The National Institute for Health and Care Excellence’s (NICE) guidance on Parkinson’s disease in adults sets out the best practice for healthcare professionals in the care, treatment, and support of people with Parkinson’s. It aims to improve the recognition and management of Parkinson’s symptoms. The NICE’s guidance on Parkinson’s disease in adults is available at the following link:
https://www.nice.org.uk/guidance/ng71
NHS RightCare has also produced a Progressive Neurology Conditions Toolkit. The toolkit sets out the key priorities for increasing knowledge of the signs and symptoms of Parkinson’s and makes suggestions regarding new service models which can be implemented in primary care to speed up referrals to specialists and ensure a timely diagnosis. Additionally, the Getting It Right First Time Programme for Neurology has published a National Speciality Report, which makes several recommendations in relation to reducing waiting for neurology services. NHS England has also established a Neurology Transformation Programme, a multi-year, clinically led programme which has developed a new model of integrated care for neurology services, to support integrated care boards to deliver the right service, at the right time for all neurology patients, including those with Parkinson’s.
Data on how regularly an average patient with Parkinson’s disease sees a neurologist is not held centrally. NICE guidance recommends that people with Parkinson's should be seen at regular intervals of six to 12 months. While NICE guidance is not mandatory, the Government expects the healthcare system and commissioners to take the guidelines fully into account when designing services for their local population, and to work towards their implementation over time.
Data on the average time taken for patients with Parkinson’s disease to see a neurologist is not held centrally. The latest data for referral to treatment waiting times in England, from February 2025, shows there were under 230,000 pathways waiting for a neurology appointment, 53.7% of which were waiting within 18 weeks.
The NHS Constitution sets out that patients should start consultant-led treatment within a maximum of 18 weeks from referral for non-urgent conditions. On 6 January 2025, NHS England published the new Elective Reform Plan, which sets out a whole system approach to hitting the 18-week referral to treatment target by the end of this Parliament. We have achieved our pledge to deliver two million extra elective appointments. These additional appointments have taken place across a number of specialities, including neurology. We have made the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the NHS constitutional standard, by March 2029.
The National Institute for Health and Care Excellence’s (NICE) guidance on Parkinson’s disease in adults sets out the best practice for healthcare professionals in the care, treatment, and support of people with Parkinson’s. It aims to improve the recognition and management of Parkinson’s symptoms. The NICE’s guidance on Parkinson’s disease in adults is available at the following link:
https://www.nice.org.uk/guidance/ng71
NHS RightCare has also produced a Progressive Neurology Conditions Toolkit. The toolkit sets out the key priorities for increasing knowledge of the signs and symptoms of Parkinson’s and makes suggestions regarding new service models which can be implemented in primary care to speed up referrals to specialists and ensure a timely diagnosis. Additionally, the Getting It Right First Time Programme for Neurology has published a National Speciality Report, which makes several recommendations in relation to reducing waiting for neurology services. NHS England has also established a Neurology Transformation Programme, a multi-year, clinically led programme which has developed a new model of integrated care for neurology services, to support integrated care boards to deliver the right service, at the right time for all neurology patients, including those with Parkinson’s.
Data on how regularly an average patient with Parkinson’s disease sees a neurologist is not held centrally. NICE guidance recommends that people with Parkinson's should be seen at regular intervals of six to 12 months. While NICE guidance is not mandatory, the Government expects the healthcare system and commissioners to take the guidelines fully into account when designing services for their local population, and to work towards their implementation over time.
Data on the average time taken for patients with Parkinson’s disease to see a neurologist is not held centrally. The latest data for referral to treatment waiting times in England, from February 2025, shows there were under 230,000 pathways waiting for a neurology appointment, 53.7% of which were waiting within 18 weeks.
The NHS Constitution sets out that patients should start consultant-led treatment within a maximum of 18 weeks from referral for non-urgent conditions. On 6 January 2025, NHS England published the new Elective Reform Plan, which sets out a whole system approach to hitting the 18-week referral to treatment target by the end of this Parliament. We have achieved our pledge to deliver two million extra elective appointments. These additional appointments have taken place across a number of specialities, including neurology. We have made the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the NHS constitutional standard, by March 2029.
There are currently no plans to publish an implementation plan alongside the Elective Reform Plan.
Our Elective Reform Plan sets out the productivity and reform efforts needed to return to the 18-week constitutional standard by the end of this Parliament, and outlines how these will be implemented by National Health Service systems, including a series of milestones for delivery. We have hit our pledge to deliver two million extra elective appointments early, and have now exceeded that pledge by delivering over three million more appointments.
In addition, the Planning Guidance for 2025/26 has since been published and confirmed the interim targets for 2025/26, including a target that 65% of patients wait for 18 weeks or less by March 2026, up from 58.9% in January 2025, with every trust expected to deliver a minimum 5% improvement on current performance over that period.
The Government is committed to putting patients first, including those waiting for joint replacement surgery.
We understand the impact long waits can have on patients’ mental health, and we are committed to ensuring that people can access high quality mental health support when they need it. As part of this, we will recruit 8,500 mental health workers to ease pressure on busy mental health services. Separately, in the Government’s Plan for Change we have committed to return to the 18-week Referral to Treatment standard, which has not been met for almost a decade.
We will ensure that patients are not only seen on time but also have the best possible experience of care. Our Elective Reform Plan, published on 6 January 2025, has committed us to working with patients and their carers to co-develop minimum standards for their experience of care.
Dedicated and protected surgical hubs are helping to reduce elective surgery wait times by focusing on high volume low complexity surgeries, such as joint replacement surgery. As of March 2025, there are 114 elective surgical hubs that are operational across England.
The Elective Reform Plan has committed to providing quicker access for patients to common surgical hub procedures by opening 17 new and expanded surgical hubs by June 2025 and ramping up the number of hubs over the next three years, so even more operations can be carried out near where patients live.
There are no plans for any of the new hubs to focus solely on orthopaedic procedures, but five of the new surgical hubs will focus on orthopaedics procedures in addition to other specialties.
The Elective Reform Plan committed to providing quicker access for patients to common surgical procedures by opening 14 new and three expanded surgical hubs by June 2025, and ramping up the number of hubs over the next three years, so more operations can be carried out. They focus on driving improvements in six high volume specialties: ophthalmology; general surgery; trauma and orthopaedics, which includes spinal surgery; gynaecology; ear, nose and throat; and urology.
The Elective Reform Plan has committed to providing quicker access for patients to common surgical hub procedures by opening 17 new and expanded surgical hubs by June 2025 and ramping up the number of hubs over the next three years, so more operations can be carried out.
In line with direction set by the Getting it Right First Time High Volume Low Complexity programme, surgical hubs focus on driving improvement in six high volume specialties: ophthalmology; general surgery; trauma and orthopaedics, which includes spinal surgery; gynaecology; ear, nose and throat; and urology. There are no plans for any of the new hubs to solely focus on orthopaedic procedures.
The Government is committed to putting patients first, including those waiting for joint replacement surgery. Too many people have been left in limbo, with their personal and professional lives on hold waiting for National Health Service treatment. We understand the impact that long waits can have on patients’ mental health, which is why we have committed, in the Government’s Plan for Change, to return to the 18-week Referral to Treatment standard, which has not been met for almost a decade.
We will ensure that patients are not only seen on time but also have the best possible experience of care. Our Elective Reform Plan, published on 6 January 2025, has committed us to working with patients and their carers to co-develop minimum standards for their experience of care.
Dedicated and protected surgical hubs are helping to reduce elective surgery wait times by focusing on high volume low complexity surgeries, such as joint replacement surgery. As of March 2025, there are 114 elective surgical hubs that are operational across England.
The Elective Reform Plan has committed to providing quicker access for patients to common surgical hub procedures by opening 17 new and expanded surgical hubs by June 2025, and by ramping up the number of hubs over the next three years, so even more operations can be carried out near where patients live.
The Government is committed to putting patients first, including those waiting for joint replacement surgery. Too many people have been left in limbo, with their personal and professional lives on hold waiting for National Health Service treatment. We understand the impact that long waits can have on patients’ mental health, which is why we have committed, in the Government’s Plan for Change, to return to the 18-week Referral to Treatment standard, which has not been met for almost a decade.
We will ensure that patients are not only seen on time but also have the best possible experience of care. Our Elective Reform Plan, published on 6 January 2025, has committed us to working with patients and their carers to co-develop minimum standards for their experience of care.
Dedicated and protected surgical hubs are helping to reduce elective surgery wait times by focusing on high volume low complexity surgeries, such as joint replacement surgery. As of March 2025, there are 114 elective surgical hubs that are operational across England.
The Elective Reform Plan has committed to providing quicker access for patients to common surgical hub procedures by opening 17 new and expanded surgical hubs by June 2025, and by ramping up the number of hubs over the next three years, so even more operations can be carried out near where patients live.
There are currently no plans to publish an implementation plan alongside the Elective Reform Plan.
Our Elective Reform Plan sets out the productivity and reform efforts needed to return to the 18-week constitutional standard by the end of this Parliament, and outlines how these will be implemented by National Health Service systems, including a series of milestones for delivery. We have already achieved our pledge to deliver two million extra elective appointments, as a first step to delivering on this commitment.
In addition, the Planning Guidance for 2025/26 has since been published and confirmed the interim targets for 2025/26, including a target that 65% of patients wait for 18 weeks or less by March 2026, up from 58.9% as of January 2025, with every trust expected to deliver a minimum 5% improvement on current performance over that period.
Infant feeding is critical to a baby’s healthy growth and development. The Government is committed to giving every child the best start in life and that includes helping families to access support to feed their baby.
Whilst breastfeeding has significant health benefits, we recognise that for those families that cannot or choose not to breastfeed, it is vital that they have access to infant formula that is affordable and high quality. Infant formula regulations ensure that all infant formula is suitable for meeting the nutritional needs of babies, regardless of the price or brand.
The Government welcomes the Competition and Markets Authority’s market study report on infant formula and follow-on formula. The report included recommendations related to clear, accurate and impartial information on the nutritional sufficiency of all infant formula products on product labelling and in retail settings as well as a recommendation related to displaying all brands of infant formula together and separate from other formula milks. We will carefully consider its findings and recommendations and respond in due course.
Infant feeding is critical to a baby’s healthy growth and development. The Government is committed to giving every child the best start in life and that includes helping families to access support to feed their baby.
Whilst breastfeeding has significant health benefits, we recognise that for those families that cannot or choose not to breastfeed, it is vital that they have access to infant formula that is affordable and high quality. Infant formula regulations ensure that all infant formula is suitable for meeting the nutritional needs of babies, regardless of the price or brand.
The Government welcomes the Competition and Markets Authority’s market study report on infant formula and follow-on formula. The report included recommendations related to clear, accurate and impartial information on the nutritional sufficiency of all infant formula products on product labelling and in retail settings as well as a recommendation related to displaying all brands of infant formula together and separate from other formula milks. We will carefully consider its findings and recommendations and respond in due course.
I refer the hon. Member to the answer I gave on 3 March 2025 to Question 33291.
The UK National Screening Committee (UK NSC) stands ready to receive the results of the GBS3 trial. The UK NSC Secretariat is in close and regular contact with the researchers. The committee will consider the evidence from the trial, once the report is available.
The Joint Committee on Vaccination and Immunisation (JCVI) has identified that maternal vaccine products to protect infants against group B streptococcus (GBS) are currently in development. A sub-committee of the JCVI will be stood up to evaluate the benefits of a GBS vaccination programme.
Should a GBS vaccine be approved for use by the Medicines and Healthcare products Regulatory Agency, the JCVI would review evidence on the safety, efficacy, impact, and cost-effectiveness of a potential vaccination programme. Based on this evidence, the JCVI would provide advice to the Department in order to develop a vaccination policy and decide on any potential future roll out in England.
Enriched culture medium testing is used in National Health Service laboratories. Current clinical practice is that if a routine urine test in pregnancy indicates a bacterial infection, microbiology techniques, such as enriched culture medium plates, should be used to identify the bacteria.
NHS England publishes planning data for the Better Care Fund, by region and local authority. This provides a breakdown of income, planned expenditure by different types of activity and planned performance against agreed metrics. The latest data is available at the following link:
https://www.england.nhs.uk/publication/better-care-fund-2023-to-2025-planning-data/
The publication includes data on planned expenditure on ‘carers services’, including by region. This expenditure will include spend on unpaid carers, but it is not possible to provide a figure for spend on unpaid carers specifically.
The Government recognises that fertility treatment across the National Health Service in England is subject to variation in access. Work continues on joint advice from the Department and NHS England about the offer around NHS-funded fertility services, including the issues for female same sex couples.
Funding decisions for health services in England are made by integrated care boards (ICBs) and are based on the clinical needs of their local population. We expect these organisations to commission fertility services in line with National Institute for Health and Care Excellence (NICE) guidelines, ensuring equal access to fertility treatment across England. NICE is currently reviewing these guidelines.
The Better Care Fund (BCF) includes funding that can be used for unpaid carer support, including short breaks and respite services for carers. As set out in the BCF policy framework published on 30 January 2025, to meet the objectives of the BCF, local areas should provide support for unpaid carers.
Funding for supporting unpaid carers is not ringfenced within the BCF. Local authorities and integrated care boards agree the amount of BCF funding in their locality that will be committed to support carers, in the context of other sources of funding and with reference to their statutory duties to support unpaid carers. As a result, actual spend by local authorities on services to support carers may differ.
The Government recognises that fertility treatment across the National Health Service in England is subject to variation in access. Work is continuing on joint advice from the Department and NHS England about the offer around NHS-funded fertility services, including the issues for female same sex couples.
Funding decisions for health services in England are made by integrated care boards and are based on the clinical needs of their local population. We expect these organisations to commission fertility services in line with National Institute for Health and Care Excellence (NICE) guidelines, ensuring equal access to fertility treatment across England. NICE is currently reviewing these guidelines.
Local authorities have a responsibility to support those caring for family and friends.
Under the Care Act 2014, local authorities must provide a range of high-quality care services, including support for carers. They are required to conduct Carer’s Assessments for individuals who may need support and to meet their eligible needs upon request.
We have already taken some steps to support carers. From April 2025, the Government will raise the Carer's Allowance earnings limit from £151 to £196 a week, the largest increase since the allowance was introduced in 1976.
Additionally, the Accelerating Reform Fund has allocated £42.6 million over 2023/24 and 2024/25 to support innovation and improve services for unpaid carers. Lord Darzi’s independent review of the National Health Service calls for a fresh approach to supporting unpaid carers, to improve outcomes for carers, those receiving care, and the NHS. We will consider these findings in our 10-Year Health Plan and in shaping future adult social care reforms.
The Government is launching an independent commission into adult social care as part of our critical first steps towards delivering a National Care Service.The Commission will start a national conversation about what working age adults, older people, and their families expect from adult social care, including exploring the needs of unpaid carers who provide vital care and support.
This Government is committed to ensuring families have the support they need. We want to ensure that people who care for family and friends are better able to look after their own health and wellbeing. Local authorities have duties to support people caring for their family and friends. The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, including support for carers such as respite and breaks.
The Government recognises the challenges facing the adult social care system. That is why the Government is launching an independent commission into adult social care as part of our critical first steps towards delivering a National Care Service.
The Commission will start a national conversation about what working age adults, older people, and their families expect from adult social care, including exploring the needs of unpaid carers who provide vital care and support. Lord Darzi’s independent review of the National Health Service is clear that a fresh approach to supporting and involving unpaid carers is required to improve outcomes for carers, people needing care and the NHS.
We will carefully consider these findings as part of our 10-year plan for reforming and modernising the NHS and as we develop plans to reform adult social care, including through the National Care Service.
Further, I recently met with employers and the Department for Business and Trade to discuss how employers are driving best practice in supporting working carers. The Government is committed to reviewing the implementation of Carer’s Leave and examining the benefits of introducing paid Carer’s Leave.
The Department holds data on the number of unpaid carers over the age of 18 receiving direct support from local authorities (LAs) in England, and the cost of this support. Data is collected from LAs in the Short and Long Term data return and the Adult Social Care Finance Return, and published in the Adult Social Care Activity and Finance Report, which is available at the following link:
No such assessment has been made by the Department. Such services are locally managed and commissioned in accordance with the population’s needs.
No assessment has been made, as health is a devolved matter and decisions on the availability of medicines in Scotland, Wales, and Northern Ireland are a matter for their own administrations.
Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE), following an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.
NICE published guidance in July 2024 on the use of Enhertu for the treatment of HER-2 low metastatic and unresectable breast cancer and was unfortunately unable to recommend it for routine NHS funding. I understand that NICE and NHS England have sought to apply as much flexibility as they can in their considerations of Enhertu for HER2-low breast cancer, and have made it clear to the companies that their pricing of the drug remains the only obstacle to access.
Ministers met with the manufacturers of Enhertu, AstraZeneca, and Daiichi Sankyo in November 2024, to encourage them to re-engage in commercial discussions with NHS England. Despite NICE and NHS England offering unprecedented flexibilities, the companies were unable to offer Enhertu at a cost-effective price. NICE’s guidance, published in July 2024, will therefore remain unchanged. Although the deadline for a rapid review has now passed, NICE has reassured me that the door remains open for the companies to enter into a new NICE appraisal if they are willing to offer Enhertu at a cost-effective price.
We are committed to improving care and support for people with myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). We recognise how devastating the symptoms can be, and the significant impact they can have on patients and their families.
The Department has reconvened the ME/CFS Task and Finish Group, including senior Department and cross-Government officials, ME/CFS specialists and representatives from NHS England, the National Institute for Health and Care Excellence, the devolved administrations, and ME/CFS charities and organisations. With stakeholder engagement via the ME/CFS Task and Finish Group, we are developing the final delivery plan for ME/CFS, which we aim to publish by the end of March. The plan will focus on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.
The Department is also working with NHS England to develop an e-learning programme on ME/CFS for healthcare professionals, with the aim of supporting staff to be able to provide better care and improve patient outcomes. Sessions one and two of the e-learning programme are now available. The third session will become available later in 2025.
The Medical Schools Council will promote the NHS England e-learning programme on ME/CFS to all United Kingdom medical schools, and encourage those medical schools to provide undergraduates with direct patient experience of ME/CFS. The General Medical Council (GMC) is the regulator of medical schools, and it is important that education is reenforced at different stages of medical training. Royal colleges play an important role in this. The GMC has included ME/CFS in the content map for the new national exam, so all medical schools will need to teach it as a subject.
NHS England is currently undertaking a stocktake, commissioned in September 2024 and due at the end of January 2025, that will provide a more accurate, in-depth overview of the position of post-COVID-19 services across England. The scope of this commission has been extended to include ME/CFS services.
The Government and NHS England support the clinical case for services which help to prevent fragility fractures and support the patients who sustain them. According to the Fracture Liaison Service Database 2022, at least 60 trusts in England had access to a Fracture Liaison Service. My Rt Hon. Friend, the Secretary of State for Health and Social Care is committed to rolling out fracture liaison services across every part of the country by 2030.
Ensuring that the United Kingdom is prepared for a future pandemic is a top priority for the Government, and we are embedding lessons from the COVID-19 pandemic within our approach to pandemic preparedness.
Whilst we cannot predict the exact timing or characteristics of a future pandemic, the Department acknowledges the disproportionate impact of pandemics on particular groups, including the immunocompromised and those who are otherwise clinically vulnerable.
The Department’s new strategic approach to pandemic preparedness recognises that pandemic planning needs to take account of all health inequalities.
COVID-19 tests and treatments are a National Health Service role at the present time. The UK Health Security Agency and NHS partners have met recently to discuss system wide communications on the testing and treatment pathways for COVID-19, to ensure that those who are eligible can access these without delay.
There are currently no discussions planned with representatives of Forgotten Lives UK.
Department officials regularly discuss a range of topics with the National Institute for Health and Care Excellence (NICE), including progress with specific appraisals, such as for sipavibart.
The NICE started its appraisal of the medicine sipavibart for preventing COVID-19, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be licensed in the United Kingdom, with the aim of publishing guidance as soon as possible, if a licence was granted. At present, the NICE appraisal is suspended as AstraZeneca has been unable to provide an evidence submission as planned. The NICE is currently awaiting notification from AstraZeneca on when it can make a submission, and will update stakeholders in due course.
If sipavibart is recommended as clinically and cost effective by the NICE, the National Health Service in England will be legally required to fund sipavibart for eligible patients in line with the NICE’s recommendations, normally within three months of final guidance being published.
As part of the 2023 England Rare Disease Action Plan, NHS England’s Genomics Education Programme has developed GeNotes, to increase the awareness of genetic and rare diseases amongst healthcare professionals. GeNotes puts information on genetic and rare diseases at the fingertips of healthcare professionals, including general practitioners. The GeNotes resource has a cardiology speciality section and includes several pages on cardiomyopathies. Further information on GeNotes more generally and about the cardiology speciality section specifically is available, respectively, at the following two links:
https://www.genomicseducation.hee.nhs.uk/genotes/
https://www.genomicseducation.hee.nhs.uk/genotes/cardiology/
Furthermore, cardiac networks of care, established locally to ensure joined up patient pathways, provide support in raising awareness of inherited cardiac conditions, including cardiomyopathy, across healthcare providers, in accordance with the services specification for inherited cardiac conditions, which is available at the following link:
https://www.england.nhs.uk/publication/cardiology-inherited-cardiac-conditions-all-ages/